Title: Vitamin B6 ameliorates acute pancreatitis by suppressing the Caspase3 signaling pathway
Version: 1 Date: 25 Nov 2023
Reviewer:  Li-Kang Sun
Reviewer's report:
To the manuscript, which entitled “Vitamin B6 ameliorates acute pancreatitis by suppressing the
Caspase3 signaling pathway”, Authors expect to understand more of the developing mechanism
of acute pancreatitis, therefore to improve the current not optimal clinical treatment related to
acute pancreatitis. This is interesting idea, the design of this study is good, the story is easy to
follow, and all of the experiments are well presented. This study were permitted from the local
Ethics committee. However, there are some augmentations needs to discuss/improve:
First at all, the major point, current acute pancreatitis was defined as an inflammatory
disease, the pathological change were focused on inflammation and necrosis; the characteristic
changes of taurocholate sodium induced pancreatitis model were inflammation and necrosis,
too. The authors presented experiments demonstrated that, Vit.B6 pre-treatment ameliorates
acute pancreatitis, this effect is possibly correlated with protein syntheses of Bax and Bcl2,
and therefore authors emphasized “Vitamin B6 ameliorates acute pancreatitis by suppressing
the Caspase3 signaling pathway”. Historical scientists believed that, acute pancreatitis, acute
recurrent pancreatitis, chronic pancreatitis are different disease, more recently believed scientists
that, there are the same disease in different phases. Whatever, pre-treat the disease model to
demonstrate these clinical effects to an acute disease like acute pancreatitis are not common, it
is difficult let physicians and so the scientists to follow and accept the logic of this conclusion.
More depth discussion are required.
Second, the evaluation of pathological changes are the critical part of this paper, I would
like strong suggest the authors present the related data in detail: for example, the contains of
the pathological changes, the table of the power scores in detail, the H&E and IF staining
presentation by choice different fold of magnification, and describe the changes in detail (with
Arrows). Special, with such high percentage detectable apoptosis cells as authors would like to
do, please choice different fold of magnification, and shown the no apoptotic part of pancreatic
tissue together in one.
Third, not really the minor point, there are different linguistic problems and spelling problems,
please check carefully before resubmission. Additionally, something strongly surprised me, the
literature reference editing the authors per hand, without use such program as usual.
Title: Vitamin B6 ameliorates acute pancreatitis by suppressing the Caspase3 signaling pathway
Version: 1 Date: 25 Nov 2023
Reviewer:  Li-Kang Sun
Reviewer's report:
To the manuscript, which entitled “Vitamin B6 ameliorates acute pancreatitis by suppressing the
Caspase3 signaling pathway”, Authors expect to understand more of the developing mechanism
of acute pancreatitis, therefore to improve the current not optimal clinical treatment related to
acute pancreatitis. This is interesting idea, the design of this study is good, the story is easy to
follow, and all of the experiments are well presented. This study were permitted from the local
Ethics committee. However, there are some augmentations needs to discuss/improve:
First at all, the major point, current acute pancreatitis was defined as an inflammatory
disease, the pathological change were focused on inflammation and necrosis; the characteristic
changes of taurocholate sodium induced pancreatitis model were inflammation and necrosis,
too. The authors presented experiments demonstrated that, Vit.B6 pre-treatment ameliorates
acute pancreatitis, this effect is possibly correlated with protein syntheses of Bax and Bcl2,
and therefore authors emphasized “Vitamin B6 ameliorates acute pancreatitis by suppressing
the Caspase3 signaling pathway”. Historical scientists believed that, acute pancreatitis, acute
recurrent pancreatitis, chronic pancreatitis are different disease, more recently believed scientists
that, there are the same disease in different phases. Whatever, pre-treat the disease model to
demonstrate these clinical effects to an acute disease like acute pancreatitis are not common, it
is difficult let physicians and so the scientists to follow and accept the logic of this conclusion.
More depth discussion are required.
Second, the evaluation of pathological changes are the critical part of this paper, I would
like strong suggest the authors present the related data in detail: for example, the contains of
the pathological changes, the table of the power scores in detail, the H&E and IF staining
presentation by choice different fold of magnification, and describe the changes in detail (with
Arrows). Special, with such high percentage detectable apoptosis cells as authors would like to
do, please choice different fold of magnification, and shown the no apoptotic part of pancreatic
tissue together in one.
Third, not really the minor point, there are different linguistic problems and spelling problems,
please check carefully before resubmission. Additionally, something strongly surprised me, the
literature reference editing the authors per hand, without use such program as usual.
Please review this paper.
user
Title: Vitamin B6 ameliorates acute pancreatitis by suppressing the Caspase3 signaling pathway
Version: 1 Date: 25 Nov 2023
Reviewer:  Li-Kang Sun
Reviewer's report:
To the manuscript, which entitled “Vitamin B6 ameliorates acute pancreatitis by suppressing the
Caspase3 signaling pathway”, Authors expect to understand more of the developing mechanism
of acute pancreatitis, therefore to improve the current not optimal clinical treatment related to
acute pancreatitis. This is interesting idea, the design of this study is good, the story is easy to
follow, and all of the experiments are well presented. This study were permitted from the local
Ethics committee. However, there are some augmentations needs to discuss/improve:
First at all, the major point, current acute pancreatitis was defined as an inflammatory
disease, the pathological change were focused on inflammation and necrosis; the characteristic
changes of taurocholate sodium induced pancreatitis model were inflammation and necrosis,
too. The authors presented experiments demonstrated that, Vit.B6 pre-treatment ameliorates
acute pancreatitis, this effect is possibly correlated with protein syntheses of Bax and Bcl2,
and therefore authors emphasized “Vitamin B6 ameliorates acute pancreatitis by suppressing
the Caspase3 signaling pathway”. Historical scientists believed that, acute pancreatitis, acute
recurrent pancreatitis, chronic pancreatitis are different disease, more recently believed scientists
that, there are the same disease in different phases. Whatever, pre-treat the disease model to
demonstrate these clinical effects to an acute disease like acute pancreatitis are not common, it
is difficult let physicians and so the scientists to follow and accept the logic of this conclusion.
More depth discussion are required.
Second, the evaluation of pathological changes are the critical part of this paper, I would
like strong suggest the authors present the related data in detail: for example, the contains of
the pathological changes, the table of the power scores in detail, the H&E and IF staining
presentation by choice different fold of magnification, and describe the changes in detail (with
Arrows). Special, with such high percentage detectable apoptosis cells as authors would like to
do, please choice different fold of magnification, and shown the no apoptotic part of pancreatic
tissue together in one.
Third, not really the minor point, there are different linguistic problems and spelling problems,
please check carefully before resubmission. Additionally, something strongly surprised me, the
literature reference editing the authors per hand, without use such program as usual.
assistant